Does reduction of treatment frequency and UVA dose substantially compromise the antipsoriatic effect of oral psoralen-UVA?
Reducing treatment frequency and UVA dose does not substantially compromise the therapeutic efficacy of PUVA.
A low ratio of testosterone to prostate specific antigen is an independent predictor of prostate cancer in hypogonadal men with prostate specific antigen 4.0 ng/ml or less. Ratios less than 1.8 were associated with a greater than 3-fold increase in prostate cancer risk.